Find Tirzepatide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2023788 19 2, Oyn3cci6qe, Ly3298176
Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist (RA), showed significantly greater glucose control and weight loss compared to the selective GLP-1 RA dulaglutide (DU) in a 26-week, randomized, double-blind Phase 2b study of type 2 diabetes patients.

API SUPPLIERS

read-more
read-more

01

Neuland Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNeuland Laboratories- A dedicated 100% API provider.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Neuland

02

Rochem International Inc

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Rochem

03

Chongqing Sintaho Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChongqing Sintaho Pharma: A trusted partner globally for chemosynthetic APIs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Chongqing Sintaho Pharmaceutical

04

Beijing Mesochem Technology

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMesochem is focused on incessant innovation along with the R&D of new APIs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Mesochem Company Banner

05

Transo-Pharm USA LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF US arrow-down AUDIT
Transo Pharm USA Company Banner

06

Shanghai Minbiotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shanghai Minbiotech CB

07

USV Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothUSV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
USV Private Limited

08

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI offers customized CDMO Solutions for API development and manufacturing services.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

09

Sinopep Pharmaceutical Inc

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Sinopep Pharmaceutical Inc

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

10

Shenzhen JYMed Technology

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Shenzhen JYMed Technology

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

Biotech Showcase
Not Confirmed
arrow
arrow
Biotech Showcase
Not Confirmed

TIRZEPATIDE

NDC Package Code : 0002-0770

Start Marketing Date : 2023-06-20

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

Biotech Showcase
Not Confirmed
arrow
arrow
Biotech Showcase
Not Confirmed

TIRZEPATIDE

NDC Package Code : 82891-022

Start Marketing Date : 2024-06-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

03

Biotech Showcase
Not Confirmed
arrow
arrow
Biotech Showcase
Not Confirmed

TIRZEPATIDE

NDC Package Code : 14403-0020

Start Marketing Date : 2024-06-26

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1mg/mg)

Marketing Category : BULK INGREDIENT

blank

04

Biotech Showcase
Not Confirmed
arrow
arrow
Biotech Showcase
Not Confirmed

TIRZEPATIDE

NDC Package Code : 14403-0017

Start Marketing Date : 2024-04-26

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

05

Biotech Showcase
Not Confirmed
arrow
arrow
Biotech Showcase
Not Confirmed

TIRZEPATIDE

NDC Package Code : 73569-050

Start Marketing Date : 2023-12-29

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

06

Hangzhou XinHan Biopharma Co., Ltd.

Country
Biotech Showcase
Not Confirmed
arrow

Hangzhou XinHan Biopharma Co., Ltd.

Country
arrow
Biotech Showcase
Not Confirmed

TIRZEPATIDE

NDC Package Code : 84789-102

Start Marketing Date : 2024-10-09

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

07

MAEDA INC

Country
Biotech Showcase
Not Confirmed
arrow

MAEDA INC

Country
arrow
Biotech Showcase
Not Confirmed

TIRZEPATIDE

NDC Package Code : 86184-392

Start Marketing Date : 2024-03-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

08

Harbin Jixianglong Biotech Co., Ltd...

Country
Biotech Showcase
Not Confirmed
arrow

Harbin Jixianglong Biotech Co., Ltd...

Country
arrow
Biotech Showcase
Not Confirmed

TIRZEPATIDE

NDC Package Code : 84385-101

Start Marketing Date : 2024-09-06

End Marketing Date : 2025-12-31

Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (100g/100g)

Marketing Category : BULK INGREDIENT

blank

09

Hangzhou Hotide Biotech Co.,Ltd

Country
Biotech Showcase
Not Confirmed
arrow

Hangzhou Hotide Biotech Co.,Ltd

Country
arrow
Biotech Showcase
Not Confirmed

TIRZEPATIDE

NDC Package Code : 83783-001

Start Marketing Date : 2024-11-10

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

10

Hangzhou Sinodo Pharm Technology Co...

Country
Biotech Showcase
Not Confirmed
arrow

Hangzhou Sinodo Pharm Technology Co...

Country
arrow
Biotech Showcase
Not Confirmed

TIRZEPATIDE

NDC Package Code : 82907-897

Start Marketing Date : 2023-09-08

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (50g/50g)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

read-more
read-more

01

LinkChem

China
PharmaVenue
Not Confirmed
arrow

LinkChem

China
PharmaVenue
Not Confirmed
arrow

CAS Number : 134979-01-4

End Use API : Tirzepatide

About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

blank

02

LinkChem

China
PharmaVenue
Not Confirmed
arrow

LinkChem

China
PharmaVenue
Not Confirmed
arrow

CAS Number : 1143516-05-5

End Use API : Tirzepatide

About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

blank

03

LinkChem

China
PharmaVenue
Not Confirmed
arrow

LinkChem

China
PharmaVenue
Not Confirmed
arrow

CAS Number : 1069067-08-8

End Use API : Tirzepatide

About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Eli Lilly

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 2.5MG/0.5ML (2.5MG/0.5ML)

Packaging :

Approval Date : 2022-05-13

Application Number : 215866

Regulatory Info : RX

Registration Country : USA

blank

02

Eli Lilly

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 10MG/0.5ML (10MG/0.5ML)

Packaging :

Approval Date : 2022-05-13

Application Number : 215866

Regulatory Info : RX

Registration Country : USA

blank

03

Eli Lilly

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 2.5MG/0.5ML (2.5MG/0.5ML)

Packaging :

Approval Date : 2023-07-28

Application Number : 215866

Regulatory Info : RX

Registration Country : USA

blank

04

Eli Lilly

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 10MG/0.5ML (10MG/0.5ML)

Packaging :

Approval Date : 2023-07-28

Application Number : 215866

Regulatory Info : RX

Registration Country : USA

blank

05

Eli Lilly

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

TIRZEPATIDE

Brand Name : ZEPBOUND (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 2.5MG/0.5ML (2.5MG/0.5ML)

Packaging :

Approval Date : 2023-11-08

Application Number : 217806

Regulatory Info : RX

Registration Country : USA

blank

06

Eli Lilly

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

TIRZEPATIDE

Brand Name : ZEPBOUND (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 10MG/0.5ML (10MG/0.5ML)

Packaging :

Approval Date : 2023-11-08

Application Number : 217806

Regulatory Info : RX

Registration Country : USA

blank

07

Eli Lilly

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

TIRZEPATIDE

Brand Name : ZEPBOUND

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 2.5MG/0.5ML (2.5MG/0.5ML)

Packaging :

Approval Date : 2024-03-28

Application Number : 217806

Regulatory Info : RX

Registration Country : USA

blank

08

Eli Lilly

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

TIRZEPATIDE

Brand Name : ZEPBOUND

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 10MG/0.5ML (10MG/0.5ML)

Packaging :

Approval Date : 2024-03-28

Application Number : 217806

Regulatory Info : RX

Registration Country : USA

blank

09

Eli Lilly

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Tirzepatid

Brand Name : Mounjaro

Dosage Form : Solution for injection in a pre-filled pen

Dosage Strength : 2.5 mg

Packaging : Pre-filled pen 4 0.5ml

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

10

Eli Lilly

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eli Lilly

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO

Dosage Form : SOLUTION

Dosage Strength : 2.5MG/0.5ML

Packaging :

Approval Date :

Application Number : 2541041

Regulatory Info :

Registration Country : Canada

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 2.5MG/0.5ML (2.5MG/0.5ML)

Approval Date : 2022-05-13

Application Number : 215866

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

02

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 5MG/0.5ML (5MG/0.5ML)

Approval Date : 2022-05-13

Application Number : 215866

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

03

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 7.5MG/0.5ML (7.5MG/0.5ML)

Approval Date : 2022-05-13

Application Number : 215866

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

04

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 10MG/0.5ML (10MG/0.5ML)

Approval Date : 2022-05-13

Application Number : 215866

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

05

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

TIRZEPATIDE

Brand Name : MOUNJARO (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 12.5MG/0.5ML (12.5MG/0.5ML)

Approval Date : 2022-05-13

Application Number : 215866

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

06

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

TIRZEPATIDE

Brand Name : ZEPBOUND (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 10MG/0.5ML (10MG/0.5ML)

Approval Date : 2023-11-08

Application Number : 217806

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

07

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

TIRZEPATIDE

Brand Name : ZEPBOUND (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 12.5MG/0.5ML (12.5MG/0.5ML)

Approval Date : 2023-11-08

Application Number : 217806

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

08

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

TIRZEPATIDE

Brand Name : ZEPBOUND (AUTOINJECTOR)

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 15MG/0.5ML (15MG/0.5ML)

Approval Date : 2023-11-08

Application Number : 217806

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

09

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

TIRZEPATIDE

Brand Name : ZEPBOUND

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 2.5MG/0.5ML (2.5MG/0.5ML)

Approval Date : 2024-03-28

Application Number : 217806

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

10

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

TIRZEPATIDE

Brand Name : ZEPBOUND

Dosage Form : SOLUTION;SUBCUTANEOUS

Dosage Strength : 5MG/0.5ML (5MG/0.5ML)

Approval Date : 2024-03-28

Application Number : 217806

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Tirzepatid

Brand Name : Mounjaro

Dosage Form : Solution for injection in a pre-filled pen

Dosage Strength : 2.5 mg

Packaging : Pre-filled pen 4 0.5ml

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Tirzepatid

Brand Name : Mounjaro

Dosage Form : Solution for injection in a pre-filled pen

Dosage Strength : 5 mg

Packaging : Pre-filled pen 4 0.5ml

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

03

Orifarm AS

Denmark
BIO Partnering at JPM
Not Confirmed
arrow

Orifarm AS

Denmark
arrow
BIO Partnering at JPM
Not Confirmed

Tirzepatid

Brand Name : Mounjaro

Dosage Form : Solution for injection

Dosage Strength : 2.5 mg

Packaging : Vials 1 0.5ml

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercepharma.com/marketing/lillys-zepbound-expected-surpass-novos-wegovy-dominate-obesity-market-globaldata

FIERCE PHARMA
02 Jan 2025

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-asks-join-lawsuit-over-compounded-versions-its-weight-loss-drugs-2025-01-02/

REUTERS
02 Jan 2025

https://www.fiercepharma.com/pharma/lilly-looks-wade-legal-fracas-between-fda-and-compounders-following-end-tirzepatide-shortage

FIERCE PHARMA
02 Jan 2025

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-obesity-drug-mounjaro-be-offered-britains-nhs-after-watchdog-nod-2024-12-23/

REUTERS
26 Dec 2024

https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea

FDA
23 Dec 2024

https://www.biospace.com/business/fda-still-undecided-about-shortage-status-of-lillys-tirzepatide

BIOSPACE
20 Dec 2024

Global Sales Information

Do you need Business Intel? Ask us

Finished Drug Prices

read-more
read-more

01

Brand Name : Mounjaro

Denmark
arrow
PharmaVenue
Not Confirmed

Brand Name : Mounjaro

Denmark
arrow
PharmaVenue
Not Confirmed

Tirzepatide

Dosage Form : Solution for injection

Dosage Strength : 2.5 mg

Price Per Pack (Euro) : 50.14

Published in :

Country : Norway

RX/OTC/DISCN :

blank

02

Brand Name : Mounjaro

U.S.A
arrow
PharmaVenue
Not Confirmed

Brand Name : Mounjaro

U.S.A
arrow
PharmaVenue
Not Confirmed

Tirzepatide

Dosage Form : Solution for injection in a pre-...

Dosage Strength : 2.5 mg

Price Per Pack (Euro) : 200.54

Published in :

Country : Norway

RX/OTC/DISCN :

blank

03

Brand Name : Mounjaro

U.S.A
arrow
PharmaVenue
Not Confirmed

Brand Name : Mounjaro

U.S.A
arrow
PharmaVenue
Not Confirmed

Tirzepatide

Dosage Form : Solution for injection in a pre-...

Dosage Strength : 5 mg

Price Per Pack (Euro) : 200.54

Published in :

Country : Norway

RX/OTC/DISCN :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Mounjaro

Tirzepatide

arrow
PharmaVenue
Not Confirmed

Brand Name : Mounjaro

U.S.A
arrow
PharmaVenue
Not Confirmed

Tirzepatide

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 483

2021 Revenue in Millions : 0

Growth (%) : New Launch in 2022

blank

02

Brand Name : Mounjaro

Tirzepatide

arrow
PharmaVenue
Not Confirmed

Brand Name : Mounjaro

U.S.A
arrow
PharmaVenue
Not Confirmed

Tirzepatide

Main Therapeutic Indication : Diabetes

Currency : USD

2023 Revenue in Millions : 5,163

2022 Revenue in Millions : 483

Growth (%) : 970

blank

03

Brand Name : Zepbound

Tirzepatide

arrow
PharmaVenue
Not Confirmed

Brand Name : Zepbound

U.S.A
arrow
PharmaVenue
Not Confirmed

Tirzepatide

Main Therapeutic Indication : Nutritional Deficiency

Currency : USD

2023 Revenue in Millions : 176

2022 Revenue in Millions : 0

Growth (%) : New Launch

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty